GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGM Biosciences Inc (STU:1K0) » Definitions » Short Percentage of Float

IGM Biosciences (STU:1K0) Short Percentage of Float


View and export this data going back to 2019. Start your Free Trial

What is IGM Biosciences Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of IGM Biosciences's Short Percentage of Float

For the Biotechnology subindustry, IGM Biosciences's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGM Biosciences's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGM Biosciences's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where IGM Biosciences's Short Percentage of Float falls into.


IGM Biosciences (STU:1K0) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGM Biosciences Inc (STU:1K0) » Definitions » Short Percentage of Float
Comparable Companies
OVID VNDA DRTS YMAB XERS NRIX CMPX CELC AVIR ACIU OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IGMS:USA
Address
325 East Middlefield Road, Mountain View, CA, USA, 94043
Website
https://www.igmbio.com
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

IGM Biosciences (STU:1K0) Headlines

No Headlines